Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Leniolisib in Immunodeficiency. The expected timing is based on the latest available company guidance and may change.
07/30/26:- Ph2 PID readouts now expected Q4 2026; single CVID Ph3 trial anticipated.
Verification
Confirm timing and program details against the company announcement or filing.